- Home
- TSI vs DSGN Comparison
TSI vs DSGN Comparison
Compare TSI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- DSGN
- Stock Information
- Founded
- TSI 1987
- DSGN 2017
- Country
- TSI United States
- DSGN United States
- Employees
- TSI N/A
- DSGN N/A
- Industry
- TSI Investment Managers
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- DSGN Health Care
- Exchange
- TSI Nasdaq
- DSGN Nasdaq
- Market Cap
- TSI 237.0M
- DSGN 264.4M
- IPO Year
- TSI N/A
- DSGN 2021
- Fundamental
- Price
- TSI $4.96
- DSGN $5.80
- Analyst Decision
- TSI
- DSGN Hold
- Analyst Count
- TSI 0
- DSGN 3
- Target Price
- TSI N/A
- DSGN $7.00
- AVG Volume (30 Days)
- TSI 106.8K
- DSGN 140.3K
- Earning Date
- TSI 01-01-0001
- DSGN 11-07-2024
- Dividend Yield
- TSI 7.46%
- DSGN N/A
- EPS Growth
- TSI N/A
- DSGN N/A
- EPS
- TSI N/A
- DSGN N/A
- Revenue
- TSI N/A
- DSGN N/A
- Revenue This Year
- TSI N/A
- DSGN N/A
- Revenue Next Year
- TSI N/A
- DSGN N/A
- P/E Ratio
- TSI N/A
- DSGN N/A
- Revenue Growth
- TSI N/A
- DSGN N/A
- 52 Week Low
- TSI $4.48
- DSGN $2.13
- 52 Week High
- TSI $4.87
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- TSI 41.31
- DSGN 50.20
- Support Level
- TSI $4.91
- DSGN $5.32
- Resistance Level
- TSI $5.11
- DSGN $7.77
- Average True Range (ATR)
- TSI 0.06
- DSGN 0.58
- MACD
- TSI -0.01
- DSGN 0.05
- Stochastic Oscillator
- TSI 21.43
- DSGN 27.57
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.